Abstract

PURPOSE: Combination bronchodilatator therapy for chronic obstructive pulmonary disease (COPD) is available widely throughout the world. The subjects of reversibility to bronchodilatators in COPD has proven to be controversal.The aim of this stady was to determine the acute effect of salbutamol (S), Ipratropium bromide ( IB ), fixed combination Ipratropium bromide + Fenoterol (Berodual), Salbutamol and Ipratropium bromid (S,IB) by nebuliser on lung function in COPD patients.

RESULTS: There was significantly important bronchodilatation (FEV1,FVC) after all drugs.Significant of of improvement was evaluated by variance analysis test.Analysis of forced expiratory volume (FEV1) curves on those test days indicated that combination was superior to either single agent alone in a peak effect, in the effect during the first 6 h after inhalation. The mean peak percent increase in FEV1 over baseline were 38% for Berodual, to 33 % for combination S+IB, to 26% for IB, and 27% for S. The difference between the combination and its component were statistically significant on all test days. Similar changes were noted in the forced vital capacity curves.

CONCLUSION: We concluded that most patients with COPD do have a component of bronchodilatator reversibility. The combination of ipratropium bromide and fenoterol or spalmotil, when given by nebulisation to patients with COPD, is more effective than either of alone. The advantage of the combination is apparent primarily during the first 6 h after inhalation.

CLINICAL IMPLICATIONS: These results confirm that combination of ipratropium and formoterol/salbutamol is superior to either of individual agents alone for identifying reversibility in pulmonary function tests in patients with COPD.

Copyright in the material you requested is held by the American College of Chest Physicians (unless otherwise noted).
This email ability is provided as a courtesy, and by using it you agree that that you are requesting the material
solely for personal, non-commercial use, and that it is subject to the American College of Chest Physicians’ Terms of Use.
The information provided in order to email this topic will not be used to send unsolicited email, nor will it be
furnished to third parties. Please refer to the American College of Chest Physicians’ Privacy Policy for further information.

Forgot your password?

Enter your username and email address. We'll send you a reminder to the email address on record.

Username
(required)

Email Address
(required)

Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.